Akela Pharma initiates its first abuse deterrent opioid Phase I clinical trial



    www.akelapharma.com
    Toronto Stock Exchange Symbol: AKL

    MONTREAL, March 6 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that it has started its first EDACS(TM) product
Phase I clinical trial. EDACS(TM) is Akela's patent pending platform
technology to prevent abuse of controlled substances.
    This Phase I trial for the first EDACS(TM) based product is an
open-label, randomized, single-dose, cross-over study investigating the
pharmacokinetics and safety of 3 different extended release formulations of a
well-known opioid product compared to the same opioid drug immediate release
formulation. The study will be carried out in 12 healthy subjects, and the
results are expected to be available in Q3/2008.
    "The abuse of prescription drugs is approaching epidemic proportions in
numerous countries. The costs to society associated with this abuse are
tremendous. Akela has developed a platform technology to prevent the abuse of
such substances by preventing the tampering of extended release dosage forms
as well as unintentional dose dumping in alcohol. " said Dr. Halvor Jaeger,
Chief Executive Officer of Akela Pharma Inc. "We believe that our platform
technology is perfectly suited to meet the increasing market demand as well as
regulatory pressure for abuse deterrent formulations."

    About EDACS(TM):

    EDACS(TM) is a patent pending platform technology which utilizes
extrusion technology to prepare an insoluble matrix containing dispersed drug
which can be shaped into tablets. The matrix is water insoluble, slightly
soluble in ethanol, not friable, does not break on compression or allow for
crushing and inhalation and does not allow for dissolution and injection.

    About Akela Pharma Inc.:

    Akela Pharma is an integrated drug development company focused on
developing therapies for the growing multi-billion dollar inhalation and pain
markets. Its lead product, for the treatment of breakthrough cancer pain, is a
fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry
powder inhaler platform. Its pipeline also includes therapeutics for asthma,
COPD, growth hormone deficiencies and controlled substance abuse deterrent
formulations.
    Akela's common shares trade on The Toronto Stock Exchange ("TSX") under
the symbol "AKL" with 11.7 million shares outstanding.

    This news release contains certain forward-looking statements that
reflect the current views and/or expectations of Akela Pharma Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
    %SEDAR: 00003466EF




For further information:

For further information: visit Akela's website at www.akelapharma.com,
or contact: Frédéric Dumais, Vice-President, Investor Relations, (514)
315-3330 ext. 106, Fax: (514) 315-3325

Organization Profile

Akela Pharma Inc

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890